Business context and reporting period
Filing identity differs from request metadata: the supplied filing is Graphite Bio, Inc. (Nasdaq: GRPH), not LENZ Therapeutics, Inc. It is the Form 10-K for the fiscal year ended December 31, 2022, filed March 20, 2023; it is not a standalone fourth-quarter report.
Graphite Bio was a pre-revenue gene-editing company developing therapies using targeted gene integration. After year-end, it paused and then discontinued development of its lead candidate, nula-cel, and began exploring strategic alternatives. The filing states it did not intend to continue its other programs using the same platform, while retaining early research activity in non-genotoxic conditioning.
Financial and operating highlights
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $72.8 million | $37.9 million |
| General and administrative expense | $32.9 million | $22.5 million |
| Total operating expenses | $105.6 million | $60.4 million |
| Net loss | $101.1 million | $70.8 million |
| Operating cash used | $88.0 million | $52.9 million |
Research and development expense rose $34.9 million, primarily from clinical and manufacturing activity, personnel costs, and facilities. General and administrative expense increased $10.4 million, mainly due to personnel-related costs. Interest income was $4.6 million, compared with $0.02 million in 2021; 2021 also included a $10.3 million loss from remeasurement of a preferred-stock tranche liability. Comprehensive loss was $102.1 million in 2022, including $1.0 million of unrealized investment losses. Operating margins are not meaningful because the company generated no revenue.
At December 31, 2022, cash and cash equivalents were $47.7 million, marketable securities were $235.8 million, and restricted cash was $1.7 million. Cash, cash equivalents, and marketable securities totaled $283.6 million. Total liabilities were $25.6 million, including operating lease liabilities; the filing does not identify outstanding borrowings. Accumulated deficit was $242.4 million, and stockholders’ equity was $296.3 million. The company reported $22.6 million of property and equipment, including construction in progress.
Investing activities used $241.9 million, largely reflecting purchases of marketable securities, partly offset by maturities; financing activities provided $0.6 million. Cash, cash equivalents, and restricted cash decreased $329.2 million, principally because cash was shifted into marketable securities. The company said its existing cash and investments were expected to fund operations into the fourth quarter of 2024 under its then-current operating plan; elsewhere, management stated funds were sufficient for at least 12 months following issuance of the financial statements.
Material changes, outlook, risks, and unusual items
- In January 2023, the company paused the Phase 1/2 CEDAR study after the first patient experienced serious, prolonged low blood cell counts (pancytopenia) requiring ongoing transfusions and growth-factor support. The company concluded the event was likely related to treatment. In February 2023, it discontinued nula-cel and initiated a strategic-alternatives process.
- The February 2023 restructuring was expected to reduce the workforce by approximately 50%. The company was still evaluating the related charges; most were expected to be recognized in the second quarter of 2023.
- No clinical trials were ongoing at the time described in the filing, and the company warned it might not complete a strategic transaction. Possible outcomes included a transaction or dissolution and liquidation; neither was assured. Strategic-process costs and ongoing operations could reduce cash available to stockholders.
- The company reported $283.6 million of cash and marketable securities at year-end, but stated it would need substantial additional funding if it continued operations beyond its current resources. It had an at-the-market sales agreement for up to $75 million under a shelf registration, but reported no shares issued or proceeds received under it through March 15, 2023.
- Marketable securities were available-for-sale investments with $1.0 million of unrealized losses; management said it intended and was able to hold the securities until recovery and identified no credit loss. Less than $1.0 million of cash was held in SVB operating accounts; $1.7 million of lease-related letters of credit were held there and classified as restricted cash.
- Key risks include uncertainty around strategic alternatives and the company’s remaining cash runway; the discontinued program’s safety event; limited development-stage pipeline and no product revenue; gene-editing safety, regulatory, intellectual-property and manufacturing risks; and the effects of workforce reductions and facility commitments. The planned 85,165-square-foot lease carries approximately $81 million of future minimum payments, although it had not commenced by year-end and the space was being made available for sublease.
- The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Confirm the issuer and ticker: this filing is Graphite Bio (GRPH), not LENZ Therapeutics.
- Review subsequent filings for the outcome of the strategic-alternatives process, any liquidation or transaction, and the resulting value available to common stockholders.
- Check updated cash, marketable securities, operating burn, restructuring charges, and runway after the workforce reduction and program discontinuation.
- Verify whether the $75 million ATM facility was used and assess dilution, lease obligations, and any changes to the company’s plans for its remaining research programs.
- Review subsequent disclosures about the serious adverse event and any related regulatory, legal, or operational developments.